# JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study

> **NCT06412848** · — · ACTIVE_NOT_RECRUITING · sponsor: **Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany** · enrollment: 360 (actual)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT06412848
- **Lead sponsor:** Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-05-09
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 360 (ACTUAL)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06412848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06412848, "JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06412848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*